论文部分内容阅读
目的:探讨曲美他嗪在缺血性心肌病心力衰竭治疗中临床效果。方法:病例资料来源于广州市光塔街社区卫生服务中心缺血性心肌病心力衰竭住院患者。随机分组方法将83例患者分为常规组和曲美他嗪组。常规组采用常规抗心衰方法治疗;曲美他嗪组在常规组基础上增加曲美他嗪治疗。比较两组总有效率、用药副作用发生率、干预前后患者心肌标志物指标的差异。结果:曲美他嗪组对比常规组缺血性心肌病心力衰竭临床总有效率更高,差异具有统计学意义(P<0.05);两组用药副作用发生率接近,差异无统计学意义(P>0.05)。结论:曲美他嗪在缺血性心肌病心力衰竭治疗中临床效果确切,可有效改善患者临床症状,促进其心肌功能的改善,对患者预后有益,且药物作用安全,无严重副作用。
Objective: To investigate the clinical effect of trimetazidine in the treatment of ischemic cardiomyopathy and heart failure. Methods: The case data were collected from hospitalized patients with ischemic cardiomyopathy and heart failure in Guangta Community Health Center in Guangtai, Guangzhou. 83 patients were randomly divided into routine group and trimetazidine group. The conventional group was treated with conventional anti-heart failure method; trimetazidine group was treated with trimetazidine on the basis of the conventional group. The total effective rate, the incidence of adverse drug reactions, myocardial markers in patients before and after intervention were compared. Results: The total effective rate of trimetazidine group was significantly higher than that of conventional group with ischemic cardiomyopathy (P <0.05). There was no significant difference in the incidence of side effects between the two groups (P > 0.05). Conclusion: Trimetazidine is effective in the treatment of heart failure due to ischemic cardiomyopathy. It can effectively improve the clinical symptoms and promote the improvement of myocardial function. It is beneficial to patients’ prognosis, and the drug is safe and has no serious side effects.